摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-氯-3-羟基苯基)乙酸 | 60397-70-8

中文名称
2-(4-氯-3-羟基苯基)乙酸
中文别名
——
英文名称
2-(4-chloro-3-hydroxyphenyl)acetic acid
英文别名
(4-chloro-3-hydroxy-phenyl)-acetic acid;3-hydroxy-4-chlorophenylacetic acid;4-Chloro-3-hydroxyphenylacetic acid
2-(4-氯-3-羟基苯基)乙酸化学式
CAS
60397-70-8
化学式
C8H7ClO3
mdl
——
分子量
186.595
InChiKey
RJTRVMKQVDAYDG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    57.5
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2918290000
  • 包装等级:
    III
  • 危险类别:
    9
  • 危险性防范说明:
    P273,P280,P301+P312+P330,P305+P351+P338+P310
  • 危险品运输编号:
    3077
  • 危险性描述:
    H302,H318,H410

SDS

SDS:21e0e31bb3b51589dfdd9ab098bc3ae2
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • POLYCYCLIC PYRAZOLINONE DERIVATIVE AND HERBICIDE COMPRISING SAME AS EFFECTIVE COMPONENT THEREOF
    申请人:SAGAMI CHEMICAL RESEARCH INSTITUTE
    公开号:US20160024110A1
    公开(公告)日:2016-01-28
    Provided are a polycyclic pyrazolinone derivative indicated by general formula (1) (in the formula, R 1 , X 1 , X 2 , X 3 , and Y indicate the definitions provided in the Specification) and a herbicide comprising same as effective component thereof.
    提供了一个由通式(1)表示的多环吡唑酮衍生物(在该式中,R1、X1、X2、X3和Y表示规范中提供的定义),以及包含其作为有效成分的除草剂。
  • Non-nucleoside reverse transcriptase inhibitors
    申请人:Roche Palo Alto LLC
    公开号:US20040198736A1
    公开(公告)日:2004-10-07
    This invention relates to novel pyridazinone derivatives of formula I wherein R 1 -R 4 , R 7 , R 8 and X 1 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient and processes to prepare compounds of formula I. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated 1
    这项发明涉及公式I的新型吡啶并酮衍生物,其中R1-R4、R7、R8和X1如摘要中所定义,并且其药学上可接受的盐和溶剂化合物,用公式I的化合物抑制或调节人类免疫缺陷病毒(HIV)逆转录酶的方法,含有公式I的药物组合物与至少一种溶剂、载体或赋形剂混合,并制备公式I的化合物的方法。这些化合物可用于治疗HIV和遗传相关病毒参与的疾病。
  • [EN] PURIN-6-ONE-DERIVATIVES<br/>[FR] DERIVES DE PURINE-6-ONE
    申请人:ALTANA PHARMA AG
    公开号:WO2004089953A1
    公开(公告)日:2004-10-21
    The compounds of a certain formula (I) in which e.g. R2, R3, R4 and R5 have the meanings as given below are novel effective PDE2 inhibitors. R2 is hydrogen, 1-4C-alkyl, 1-hydroxy-2-4C-alkyl, 1-4C-alkylcarbonyl or 1-(acetyloxy)-2-4C-alkyl and R3 is Arylbutyl, Heteroarylbutyl, Arylpropyl, Heteroarylpropyl, Arylethyl or Heteroarylethyl; wherein Aryl is phenyl, naphthalenyl or indanyl, each of which optionally substituted up to three times identically or differently by halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy or 1-4C-alkoxycarbonyl, Heteroaryl is pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolyl, isoquinolyl, naphthyridinyl, phthalazinyl, indolyl, isoindolyl, indazolyl, purinyl, pteridinyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl or thiophenyl, each of which optionally substituted up to three times identically or differently by halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy or 1-4C-alkoxycarbonyl, R4 is 1-4C-alkoxy which is completely or predominantly substituted by fluorine and R5 is halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1 -4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino, mono- or di-1-4C-alkylamino, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, 1-4C-alkylcarbonyloxy, 1-4C-alkylsulfonylamino, phenylcarbonylamino, phenylcarbonylamino substituted in the phenyl moiety by R6 and/or R7, benzylcarbonylamino, benzylcarbonylamino substituted in the phenyl moiety by R8 and/or R9, phenylsulfonylamino, phenylsulfonylamino substituted in the phenyl moiety by R10 and/or R11, benzylsulfonylamino or benzylsulfonylamino substituted in the phenyl moiety by R12 and/or R13.
    具有特定结构式(I)的化合物,其中例如R2、R3、R4和R5具有以下所述含义,是新颖的有效的PDE2抑制剂。R2为氢、1-4C-烷基、1-羟基-2-4C-烷基、1-4C-烷基羰基或1-(乙酰氧基)-2-4C-烷基,R3为芳基丁基、杂芳基丁基、芳基丙基、杂芳基丙基、芳基乙基或杂芳基乙基;其中芳基为苯基、萘基或茚基,每个基可选地最多被卤素、羟基、硝基、三氟甲基、羧基、1-4C-烷基、1-4C-烷氧基或1-4C-烷氧羰基取代最多三次,杂芳基为吡啶基、吡嗪基、吡啶嗪基、嘧啶基、喹唑啉基、喹喜啶基、茴啉基、喹啉基、异喹啉基、萘噻啉基、菲啉基、吲哚基、异吲哚基、吲唑基、嘌呤基、哌嗪基、苯并呋喃基、苯并噁唑基、苯并噻唑基、苯并咪唑基、噁唑基、异噁唑基、噻唑基、异噻唑基、咪唑基、吡咯基、吡唑基、呋喃基或噻吩基,每个基可选地最多被卤素、羟基、硝基、三氟甲基、羧基、1-4C-烷基、1-4C-烷氧基或1-4C-烷氧羰基取代最多三次,R4为完全或主要由氟取代的1-4C-烷氧基,R5为卤素、羟基、硝基、三氟甲基、羧基、1-4C-烷基、1-4C-烷氧基、完全或主要由氟取代的1-4C-烷氧基、1-4C-烷氧羰基、氨基、单或双1-4C-烷基氨基、氨基羰基、单或双1-4C-烷基氨基羰基、1-4C-烷基羰基氨基、1-4C-烷基羰基氧基、1-4C-烷基磺酰氨基、苯基羰基氨基、苯基羰基氨基在苯基上被R6和/或 R7取代、苄基羰基氨基、苄基羰基氨基在苯基上被R8和/或 R9取代、苯基磺酰氨基、苯基磺酰氨基在苯基上被R10和/或 R11取代、苄基磺酰氨基或苄基磺酰氨基在苯基上被R12和/或 R13取代。
  • COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION
    申请人:Brown Matthew
    公开号:US20080312270A1
    公开(公告)日:2008-12-18
    Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.
    本文提供了在治疗炎症和免疫相关疾病和病况方面有用的化合物、组合物和方法。具体而言,本发明提供了调节参与过敏性疾病、炎症病症和癌症的蛋白质的功能和/或表达的化合物。所述化合物为羧酸衍生物。
  • Compounds
    申请人:AstraZeneca AB
    公开号:US08148572B2
    公开(公告)日:2012-04-03
    The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    该发明涉及取代苯乙酸作为治疗呼吸系统疾病有用的药物化合物,包含它们的制药组合物以及其制备过程。
查看更多